Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487254 | 0.89 | TRPV1 (0.64) | NQO2TRPV1MEN1KMT2ARAB9A | |
| SCHEMBL31680675 | 0.89 | TRPV1 (0.64) | NQO2TRPV1MEN1KMT2ARAB9A | |
| SCHEMBL7714831 | 0.86 | RXFP1 (0.46) | NQO2TRPV1POLBRXFP1MEN1 | |
| SCHEMBL30077817 | 0.85 | RXFP1 (0.46) | NQO2TRPV1POLBRXFP1MEN1 | |
| SCHEMBL27453735 | 0.85 | RXFP1 (0.46) | NQO2TRPV1POLBRXFP1MEN1 | |
| SCHEMBL3729968 | 0.85 | ALDH1A1 (0.45) | NQO2TRPV1RXFP1GAAALDH1A1 | |
| SCHEMBL2396852 | 0.84 | ALDH1A1 (0.63) | MEN1KMT2AGAAALDH1A1HPGD | |
| SCHEMBL14059000 | 0.82 | CASP6 (0.68) | NQO2RXFP1MEN1KMT2AGAA | |
| SCHEMBL421016 | 0.80 | MAPK14 (0.47) | TRPV1POLBRXFP1MEN1KMT2A | |
| SCHEMBL12199919 | 0.80 | NQO2 (0.44) | NQO2TRPV1POLBRXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | BAYER CROPSCIENCE AG (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | BAYER CROPSCIENCE AG (DE) | 2012-05-24 | — | — | US | disclosed |
| CN-102414175-A | Insecticidal arylpyrrolidines | BAYER CROPSCIENCE AG | 2012-04-11 | — | — | CN | disclosed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| EP-1478646-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129854-A1 | Pesticidal Arylpyrrolidines | DDT, AADAC, AHR | NQO2 186/4885TRPV1 115/4885POLB 4780/4885 |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | NQO2 326/4885TRPV1 4489/4885POLB 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.